

## Supplementary Online Content

Cowley NJ, Owen A, Shiels SC, et al. Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. *JAMA Intern Med*. Published online April 24, 2017. doi:10.1001/jamainternmed.2017.0895

**eTable 1.** Study Drug Adjustment for Renal Impairment

**eTable 2.** Patient Baseline Characteristics

This supplementary material has been provided by the authors to give readers additional information about their work.

**eTable 1. Study Drug Adjustment for Renal Impairment**

<b>Cr<sub>Cl</sub> (ml/min)</b>	<b>Valaciclovir</b>	<b>Aciclovir</b>	<b>Valganciclovir</b>	<b>Ganciclovir</b>
>75	2g qds	10mg/kg tds	450mg od	2.5mg/kg od
51-75	1.5g qds	10mg/kg tds	450mg alt. days	1.25mg/kg od
26-50	1.5g tds	10mg/kg bd	450mg twice weekly	0.625mg/kg od
10-25	1.5g bd	10mg/kg od	225mg twice weekly	0.625mg/kg alt. days
<10 HD	1.5g od	5mg/kg od	225mg after HD	0.625mg/kg after HD
<10 CVVH	1.5g od	5mg/kg od	225mg twice weekly	0.625mg/kg od

Cr<sub>Cl</sub>=Creatinine clearance using Cockcroft-Gault formula; HD=haemodialysis; CVVH=Continuous venovenous haemofiltration; od=once daily; bd= twice daily; tds= three times daily; qds=four times daily; alt=alternate.

**eTable 2. Patient Baseline Characteristics**

		Control (N=44)	Valaciclovir (N=34)	Valganciclovir (N=46)
Age (years)	Mean (SD)	55 (17)	58 (17)	57 (17)
	Range	(21 – 88)	(24 – 82)	(20 – 86)
Sex	Male (%)	23 (52)	24 (71)	31 (67)
	Female (%)	21 (48)	10 (29)	15 (33)
Body Mass Index (kg/m <sup>2</sup> )	Median (IQR)	27 (24 - 31)	26 (22 - 28)	27 (24 - 29)
	Range	(18 – 55)	(15 – 50)	(20 – 37)
Diagnosis category at enrolment				
	Trauma	10	11	10
	Infection (respiratory)	5	5	8
	Thromboembolic/vascular	5	5	5
	Emergency general surgery	3	4	6
	Cardiac arrest	6	4	2
	Cerebrovascular / cerebral injury	3	1	5
	Infection (other)	5	1	1
	Respiratory failure	2	0	2
	Liver failure	1	1	2
	Poisoning	2	1	1
	Burn injury	1	0	2
	Elective general surgery	1	1	1
	Other	0	0	1
Length of Hospital Stay Prior to Randomisation (days)*	Median (IQR)	5 (3 - 7)	5 (2 - 6)	5 (3 - 6)
	Range	(1 – 9)	(1 – 21)	(2 – 8)
Length of ICU Stay Prior to Randomisation (days)**	Median (IQR)	4 (2 - 6)	4 (2 - 5)	4 (2 - 5)
	Range	(1 – 7)	(1 – 7)	(1 – 7)
Duration of Mechanical Ventilation prior to Randomisation (days)***	Median (IQR)	3 (2 - 5.5)	4 (2 - 5)	3 (2 - 5)
	Range	(1 – 7)	(1 – 7)	(0 – 8)
APACHE II score on ICU admission	N	41	32	43
	Mean (SD)	17.5 (7.0)	17.9 (4.6)	17.4 (6.3)
	Range	(3 – 42)	(9 – 26)	(6 – 34)
SOFA score (on day 1)	Median (IQR)	8.5 (6.5 - 13.0)	8.5 (5.0 - 12.0)	8.0 (5.0 - 11.0)
	Range	(2 – 18)	(3 – 18)	(2 – 20)
White Cell Count (x10 <sup>9</sup> /L) (on day 1)	Mean (SD)	12.5 (6.1)	12.7 (5.5)	11.3 (7.2)
	Range	(5.1 – 28.9)	(4.3 – 25.5)	(2.8 – 44.4)

SD=Standard deviation; IQR=Interquartile Range; ICU=Intensive Care Unit; APACHE II= Acute Physiology and Chronic Health Evaluation II; SOFA score=Sequential Organ Failure Assessment score;

\* defined as number of days between date of hospital admission and date of randomisation.

\*\* defined as number of days between date of ICU admission and date of randomisation.

\*\*\* defined as number of days between date of endotracheal intubation and date of randomisation.